Best Peptide for Angiogenesis & Cell Migration Research
TB-500 leads angiogenesis and cell migration research through its actin cytoskeleton regulation, endothelial tube formation promotion, and scratch wound closure acceleration. The Thymosin Beta-4 fragment is the standard for vascularization and cell motility studies.
TOP RECOMMENDATION
TB-500 — Thymosin Beta-4 Fragment (17-23)
TB-500 is the definitive peptide for angiogenesis and cell migration research. As the active fragment of Thymosin Beta-4, its primary mechanism is G-actin sequestration and cytoskeletal regulation — the fundamental biological machinery controlling cell shape, lamellipodia extension, and directional migration. Published studies demonstrate TB-500 promotes endothelial tube formation in Matrigel assays, accelerates scratch wound closure in keratinocyte monolayers, and upregulates VEGF and MMP expression in vascular cell models. While BPC-157 contributes VEGF-driven angiogenesis through growth hormone receptor upregulation, TB-500's direct actin regulation provides the mechanistic precision required for cell migration, tube formation, and vascular sprouting research.
WHY IT WINS
- Sequesters G-actin and regulates the actin cytoskeleton, directly controlling cell shape, lamellipodia formation, and directional migration
- Promotes endothelial cell migration and capillary-like tube formation in Matrigel and collagen gel angiogenesis assays at 1–50 mcg/ml
- Upregulates VEGF and matrix metalloproteinase expression in endothelial cells, driving vascular sprouting in ex-vivo aortic ring models
- Accelerates scratch wound closure in keratinocyte and fibroblast monolayers within 6–24 hours at standard research concentrations
- Systemic distribution allows research into distant-site angiogenesis without local application constraints
APPLICATION SUITABILITY MATRIX
| RESEARCH APPLICATION | TB-500 | BPC-157 |
|---|---|---|
| Endothelial Tube Formation | ||
| Scratch Wound Closure | ||
| Cell Migration (Transwell) | ||
| Aortic Ring Sprouting | ||
| VEGF Expression | ||
| Lamellipodia Dynamics | ||
| Stability in Long Studies | ||
| Cost per Experiment |
IDEAL RESEARCH APPLICATIONS
- Matrigel tube formation and vascular sprouting assays
- Scratch wound healing and cell migration studies
- Ex-vivo aortic ring angiogenesis models
- Endothelial cell proliferation and VEGF expression
- Transwell migration and invasion assays
ALTERNATIVE: BPC-157
RUNNER-UP
BPC-157 — Body Protection Compound-157
Consider when:
- VEGF-driven angiogenesis promotion offers an alternative vascularization mechanism complementary to TB-500's actin regulation
- Longer reconstituted stability (30 days vs 14 days) benefits extended angiogenesis monitoring protocols
- Lower cost makes BPC-157 attractive for high-throughput endothelial screening where actin dynamics are secondary to growth factor signaling
ANALYTICAL SPECIFICATIONS
Compound
Thymosin Beta-4 Fragment (17-23)
CAS Number
77591-33-4
Purity (HPLC)
≥ 98.8%
Molecular Weight
4,963.5 g/mol
Sequence
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Trp-Ser-Gln-Glu-Arg-Glu-Arg-Gln-Glu-Lys-Asn-Glu
Verification
HPLC + MS per batch
FREQUENTLY ASKED QUESTIONS
Why is TB-500 better than BPC-157 for angiogenesis research?
TB-500 regulates the actin cytoskeleton, which controls endothelial cell shape, lamellipodia formation, and directional migration — all essential to vascular sprouting and tube formation. BPC-157 promotes angiogenesis indirectly through VEGF upregulation. For direct cell motility and tube formation studies, TB-500's actin mechanism is more precisely relevant.
What concentration of TB-500 should I use in Matrigel tube formation assays?
For HUVEC or HMEC-1 tube formation assays in Matrigel or collagen gels, TB-500 is typically evaluated at 1–50 mcg/ml in serum-reduced media. Tube length, branch points, and network area are quantified at 4–8 hours by phase-contrast microscopy and ImageJ analysis.
Does TB-500 work in 3D spheroid angiogenesis models?
Yes. TB-500 has been evaluated in endothelial spheroid sprouting assays embedded in collagen or fibrin matrices. Its promotion of cell migration and MMP expression drives vascular sprout extension in 3D environments.
Can TB-500 and VEGF be combined in angiogenesis studies?
Yes. Many researchers evaluate TB-500 alongside VEGF-A as a positive control or in combination. TB-500's actin regulation complements VEGF's receptor-tyrosine-kinase signaling. Typical VEGF-A concentration is 10–50 ng/ml combined with TB-500 at 5–25 mcg/ml.
Is TB-500 effective in choroidal neovascularization models?
Yes. Thymosin Beta-4 (and its TB-500 fragment) has been studied in laser-induced choroidal neovascularization models. Its anti-inflammatory and angiogenic properties are relevant to ocular vascularization research.
REFERENCES
- [1]Malinda, K.M. et al. (2008). Thymosin beta4 promotes wound repair. Annals of the New York Academy of Sciences, 1112(1), 117–125.
- [2]Qiu, P. et al. (2011). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 131(5), 1117–1125.
- [3]Evans, M. et al. (2013). The regenerative peptide TB-500. Journal of Experimental & Integrative Medicine, 3(4), 287–290.
- [4]Goldstein, A.L. et al. (2012). Thymosins in health and disease. Annals of the New York Academy of Sciences, 1269(1), 1–4.
TOP RECOMMENDATION
TB-500
Thymosin Beta-4 Fragment (17-23)
QUICK LINKS
RELATED RESEARCH GOALS
RESEARCH USE ONLY. All compounds are strictly for in-vitro laboratory research by qualified professionals. Not for human consumption, veterinary use, or clinical application.